War in Iran costs $29 billion so far. And, students are finally improving in math

The Pentagon now estimates the war with Iran has cost about $29 billion, up from $25 billion two weeks ago, and says repairs to U.S. facilities hit by Iran could add at least another $4 billion. The conflict is also raising fuel and fertilizer costs for farmers, adding pressure to agriculture and broader input prices. Separately, FDA Commissioner Marty Makary resigned after 13 months, underscoring ongoing turmoil in U.S. health regulation.

Analysis

The main investable read-through is not the headline war cost itself, but the forced reallocation path: supplemental funding plus repair bills creates a second-order tailwind for defense primes, logistics, munitions, and military construction while pressuring discretionary federal outlays later this fiscal year. The market tends to underprice the lag between conflict expense recognition and contract flow; once supplemental appropriations are signaled, the beneficiaries are usually the names with existing capacity and sole-source exposure, not the broad defense index. Conversely, higher fuel and fertilizer costs transmit into farm economics with a delay, tightening margins just as growers face another seasonal planning cycle.

The more interesting political risk is that the conflict is now interacting with domestic inflation sensitivity and election positioning. That makes energy, agriculture, and chemicals a three-way feedback loop: higher input costs strengthen the case for policy relief, but policy relief is slow while commodity costs reprice immediately. If the administration leans harder into anti-pesticide or food-safety rhetoric while simultaneously defending crop-input availability, the result is likely volatility in ag-chem multiples rather than a clean secular rerating.

In healthcare, the FDA leadership change is less about the individual than about regulatory cadence. A less medically credible acting commissioner and continued confirmation friction increase odds of slower, more politicized decision-making on nicotine, food, and device rules, which raises option value for companies waiting on approvals but also increases headline risk for anything tied to public-health policy. The contrarian point: markets may overestimate how much ideological disruption can change actual agency throughput in the next 1-2 quarters; the bureaucracy often slows, but does not fully break.

The most overlooked signal is the education data: improvement in math ahead of reading implies a policy-driven rotation in school spending, curriculum, and ed-tech procurement rather than a broad rebound. If reading reform lags, capital may chase math-focused exposure first, but the bigger trade is in districts/states adopting structured literacy, where the second-order spending cycle can extend for years.

Key Decisions for Investors

• Long LMT / NOC / GD on any post-hearing weakness; thesis is supplemental defense funding and repair-related follow-through over the next 1-3 months. Use 5-7% downside stops because the trade is appropriations-driven, not earnings-driven.
• Pair long XLB agriculture-input beneficiaries with short discretionary retail exposed to farm demand compression over the next 2-4 months; rising fuel/fertilizer costs should widen the rural margin squeeze before policy relief arrives.
• Buy calls on SMH-like regulatory beneficiaries only selectively; better expression is long ICLR or PFE optionality around slower FDA cadence if approvals get pushed out by 1-2 quarters. Keep size small given headline risk and political reversals.
• Short MOS or CF against long select food producers if energy input costs keep rising; fertilizer remains the most direct transmission channel from geopolitics into ag earnings, with favorable asymmetry if crude stays firm for another 6-8 weeks.
• For education-policy exposure, favor small long positions in LRN or TWOU only if state-level structured-literacy legislation accelerates; otherwise avoid broad ed-tech until we see procurement data, since the read-through is gradual and uneven.